Pharmala Biotech Holdings (MDMA) Stock Overview
A biotechnology company, engages in the development, manufacture, and sale of MDMA and MDXX class molecules in service to the burgeoning clinical research community. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
MDMA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Pharmala Biotech Holdings Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.14 |
| 52 Week High | CA$0.20 |
| 52 Week Low | CA$0.085 |
| Beta | 0.72 |
| 1 Month Change | -12.50% |
| 3 Month Change | 40.00% |
| 1 Year Change | 27.27% |
| 3 Year Change | -64.56% |
| 5 Year Change | n/a |
| Change since IPO | 75.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| MDMA | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | 0% | 2.3% | -0.4% |
| 1Y | 27.3% | -1.0% | 30.4% |
Return vs Industry: MDMA exceeded the Canadian Biotechs industry which returned -0.7% over the past year.
Return vs Market: MDMA underperformed the Canadian Market which returned 29.5% over the past year.
Price Volatility
| MDMA volatility | |
|---|---|
| MDMA Average Weekly Movement | 26.6% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 9.7% |
| 10% most volatile stocks in CA Market | 16.4% |
| 10% least volatile stocks in CA Market | 3.7% |
Stable Share Price: MDMA's share price has been volatile over the past 3 months compared to the Canadian market.
Volatility Over Time: MDMA's weekly volatility has increased from 18% to 27% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Nick Kadysh | pharmala.ca |
Pharmala Biotech Holdings Inc., a biotechnology company, engages in the development, manufacture, and sale of MDMA and MDXX class molecules in service to the burgeoning clinical research community. It offers its MDMA drug active pharmaceutical ingredients under the LaNeo brand. The company is headquartered in Vancouver, Canada.
Pharmala Biotech Holdings Inc. Fundamentals Summary
| MDMA fundamental statistics | |
|---|---|
| Market cap | CA$15.24m |
| Earnings (TTM) | -CA$1.63m |
| Revenue (TTM) | CA$889.57k |
Is MDMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MDMA income statement (TTM) | |
|---|---|
| Revenue | CA$889.57k |
| Cost of Revenue | CA$100.90k |
| Gross Profit | CA$788.66k |
| Other Expenses | CA$2.42m |
| Earnings | -CA$1.63m |
Last Reported Earnings
Feb 28, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.015 |
| Gross Margin | 88.66% |
| Net Profit Margin | -183.55% |
| Debt/Equity Ratio | 0% |
How did MDMA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/26 19:04 |
| End of Day Share Price | 2026/06/26 00:00 |
| Earnings | 2026/02/28 |
| Annual Earnings | 2025/08/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Pharmala Biotech Holdings Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.